About the Company
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.
Employees
12
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GNPX News
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
Genprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 Antibodies
Tuesday announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent for its ...
Genprex, Inc. (2DE0.F)
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today ...
Investornewsbreaks Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent For Leading Drug Candidate To Growing International Patent Portfolio
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, ...
Investornewsbreaks Genprex Inc. (NASDAQ: GNPX) Preclinical Data To Be Presented At Upcoming AACR Annual Meeting
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, ...
Genprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor Conference
To view the full press release, visit https://ibn.fm/htjnw About Genprex Inc. Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with ...
Genprex (NASDAQ: GNPX) Phase 2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
To view the full press release, visit https://ibn.fm/D0muh About Genprex Inc. Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with ...
Genprex Inc (2DE0.MU)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Genprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 Antibodies
(RTTNews) - Genprex, Inc. (GNPX) Tuesday announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent for its lead drug candidate, Reqorsa Immunogene Therapy ...
Genprex, Inc. (2DE0.F)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...